Clinical Trials | October 09, 2022
Pfizer announces positive topline results from Phase 3 TALAPRO-2 trial
Study achieves primary endpoint of radiographic progression-free survival
Study achieves primary endpoint of radiographic progression-free survival
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Both products are broad-spectrum, foliar insecticides used across wide range of crops
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
The inspection of the facility was conducted from August 16-19, 2022.
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Subscribe To Our Newsletter & Stay Updated
